UlarSawa has been warning you guys about KANGER that this company only produce bamboo products. While the NPRA 1985 was promoting vaccines in this forum and many forums.

BUY KSRAR @0.04

No vaccines allowed to be distributed by private company. Only Government are legal to dispatch to clinics and hospitals .

Sourgrapes

Still holding some Kanger @0.195..Aiyooo

No middleman for vaccines purchase reported in parliament

No middleman reported in parliament

No middleman reported in parliament

BREAKING NEWS: Australia just cancelled an order of 51 million doses of a particular COVID-19 vaccine in trials from a company named CSL, because those that were taking it were testing positive for HIV afterward.
https://www.aljazeera.com/economy/2020/12/11/australia-cancels-order-for-vaccine-as-trial-stumbles

https://fortune.com/2020/12/10/covid-19-vaccine-australia-csl-order/?fbclid=IwAR33EvSNIHnTOLTxdfXNMw-JpwBDuvE4Hv4AjkzGgiCb-pbLnFaBPUDHrZY

https://www.reuters.com/article/us-health-coronavirus-australia-idUSKBN28K39A

BREAKING NEWS: Australia just cancelled an order of 51 million doses of a particular COVID-19 vaccine in trials from a company named CSL, because those that were taking it were testing positive for HIV afterward.
https://www.aljazeera.com/economy/2020/12/11/australia-cancels-order-for-vaccine-as-trial-stumbles

https://fortune.com/2020/12/10/covid-19-vaccine-australia-csl-order/?fbclid=IwAR33EvSNIHnTOLTxdfXNMw-JpwBDuvE4Hv4AjkzGgiCb-pbLnFaBPUDHrZY

https://www.reuters.com/article/us-health-coronavirus-australia-idUSKBN28K39A

BREAKING NEWS: Australia just cancelled an order of 51 million doses of a particular COVID-19 vaccine in trials from a company named CSL, because those that were taking it were testing positive for HIV afterward.
https://www.aljazeera.com/economy/2020/12/11/australia-cancels-order-for-vaccine-as-trial-stumbles

https://fortune.com/2020/12/10/covid-19-vaccine-australia-csl-order/?fbclid=IwAR33EvSNIHnTOLTxdfXNMw-JpwBDuvE4Hv4AjkzGgiCb-pbLnFaBPUDHrZY

https://www.reuters.com/article/us-health-coronavirus-australia-idUSKBN28K39A

Jackkin Everything are looking good for Huaan, new biz transformation, 2021 will be a good year ahead for them, if u can spend some time to study their biz plan..
16/12/2020 10:46 PM
__________________________________
Please post the link of the above? Thank you

Those are Conversion of Redeemable Structured Convertible Notes

DNeX ..no Volume

Mau bebas ppl from this Kounter baa

HOLD

If suddenly a Catfish tries to push the price up to 0.235 0r 0.240 don't chase. it will go down to 0.225-0.230 and this catfish will continue selling at that price.

The Shark (small player) pushes selling @ 0.230 since yesterday clearing his stock.

WATCH Kstar

07/12/2020 0.44 0.28 -0.16 (36.36%) HOLD PUBLIC BANK

Yong Tai (Neutral, TP: RM0.28): To raise up to RM92m via private placement. Yong Tai announced a private placement to raise up to RM92m. It said the money raised would be used to fund the development of its Impression City and Impression UThant projects, as well as for working capital. The group said the private placement will consist of up to 20% of its total number of shares to independent third party investors to be identified later. (The Edge)

I wouldn't have bought this stock if not because of the Sinopharm vaccines. Really, i am not in their pandas food plants.

https://www.facebook.com/135091239861609/posts/3593807027323329/?app=fbl
Nur Jazlan Mohd Facebook

Could anyone ask the Chairman for info.

https://www.facebook.com/135091239861609/posts/3593807027323329/?app=fbl
Nur Jazlan Mohd Facebook

Check with the chairman

Kanger International Bhd (KIB) has inked a COLLARBORATION AGREEMENT with China-based Sinopharm Group Hunan Changde Medical Co Ltd (Sinopharm Group) for the distribution of Covid-19 vaccines developed by China National Biotech Group Company (CNBG) in Malaysia.

COLLABORATION AGREEMENT meaning (A collaboration agreement is a legally binding agreement between different parties that want to co-operate together or work collaboratively on a commercial project that sets out how the parties will work together, divides the benefits, responsibilities and obligations created by or for the project between the parties...)

2323 每个合同都会保护自己公司，3.6是很正常的，你第一次看合同吗
11/12/2020 12:53 PM
Every contract will protect your company. 3.6 is normal. Is it the first time you look at the contract?
Google Translated..

(Latest Developments
3 months ago)
Kanger International Entered Collaboration Agreement With Sinopharm Group Hunan Changde Medical

Ref: https://www.reuters.com/companies/SHTDF.PK

HOLD

(Latest Developments
3 months ago)
Kanger International Entered Collaboration Agreement With Sinopharm Group Hunan Changde Medical

Ref: https://www.reuters.com/companies/SHTDF.PK

HOLD

HOLD. Target 1.00

now i am holding kanger a few kstar....just don't want to miss them.

guys, buy some ler...KSTAR

huhuhu better get some kstar....don't miss the boat....huhuhu

hopefully

Kanger has no cash

KSTAR is moving....not Kanger

This counter trap investors - correction : This counter trapped...

This company is raising RM through private placement just show this company is in a very poor financial health. This counter trap investors and kept them in with its sinopharm hope.

*yawn yawn yawn

https://klse.i3investor.com/servlets/ptres/58079.jsp

07/12/2020 YONGTAI 0.385 0.28 -0.105 (27.27%) HOLD - PUBLIC BANK

Today Top Glove released its 1QFY2021 report. You can access the full report here.

The stock has been trading at below RM7 level for the better part of the last few weeks on a myriad of news perceived as bad. Albeit all that, the company posted a net profit of RM2.38 billion for the quarter. They have approximately 8.2 billion outstanding shares. This gives the company an EPS of RM0.29 for the quarter. Let's do a bit of calculating:

- Assume the profits don't increase (they are expected to, but we will be conservative).

- This would mean an EPS of RM1.16 for FY2021.

- This translates into a forward P/E of 6 at price RM7 (as of writing this, the price is RM6.84)

This make is one of the lowest valued stocks in the entire stock market, with only 5 companies having forward P/Es of below 6 at the time of writing this.

If we assume that a stock is fairly priced at P/E 15, this would mean that the fair value of Top Glove is RM17.40.

At the same time, one of Top Glove's main competitors in the glove manufacturing market - Hartalega, has a consensus forward P/E of about 19.5 based on its current market price.

Let's assume that the market assigns the same valuation to Top Glove as it does to its direct competitor and simiarly-sized peer Hartalega. In this case, Top Glove's market price would be RM22.62.

https://klse.i3investor.com/blogs/bursainvestments/2020-12-09-story-h1...

Today Top Glove released its 1QFY2021 report. You can access the full report here.

The stock has been trading at below RM7 level for the better part of the last few weeks on a myriad of news perceived as bad. Albeit all that, the company posted a net profit of RM2.38 billion for the quarter. They have approximately 8.2 billion outstanding shares. This gives the company an EPS of RM0.29 for the quarter. Let's do a bit of calculating:

- Assume the profits don't increase (they are expected to, but we will be conservative).

- This would mean an EPS of RM1.16 for FY2021.

- This translates into a forward P/E of 6 at price RM7 (as of writing this, the price is RM6.84)

This make is one of the lowest valued stocks in the entire stock market, with only 5 companies having forward P/Es of below 6 at the time of writing this.

If we assume that a stock is fairly priced at P/E 15, this would mean that the fair value of Top Glove is RM17.40.

At the same time, one of Top Glove's main competitors in the glove manufacturing market - Hartalega, has a consensus forward P/E of about 19.5 based on its current market price.

Let's assume that the market assigns the same valuation to Top Glove as it does to its direct competitor and simiarly-sized peer Hartalega. In this case, Top Glove's market price would be RM22.62.

https://klse.i3investor.com/blogs/bursainvestments/2020-12-09-story-h1...

Today Top Glove released its 1QFY2021 report. You can access the full report here.

The stock has been trading at below RM7 level for the better part of the last few weeks on a myriad of news perceived as bad. Albeit all that, the company posted a net profit of RM2.38 billion for the quarter. They have approximately 8.2 billion outstanding shares. This gives the company an EPS of RM0.29 for the quarter. Let's do a bit of calculating:

- Assume the profits don't increase (they are expected to, but we will be conservative).

- This would mean an EPS of RM1.16 for FY2021.

- This translates into a forward P/E of 6 at price RM7 (as of writing this, the price is RM6.84)

This make is one of the lowest valued stocks in the entire stock market, with only 5 companies having forward P/Es of below 6 at the time of writing this.

If we assume that a stock is fairly priced at P/E 15, this would mean that the fair value of Top Glove is RM17.40.

At the same time, one of Top Glove's main competitors in the glove manufacturing market - Hartalega, has a consensus forward P/E of about 19.5 based on its current market price.

Let's assume that the market assigns the same valuation to Top Glove as it does to its direct competitor and simiarly-sized peer Hartalega. In this case, Top Glove's market price would be RM22.62.

https://klse.i3investor.com/blogs/bursainvestments/2020-12-09-story-h1...

Today Top Glove released its 1QFY2021 report. You can access the full report here.

The stock has been trading at below RM7 level for the better part of the last few weeks on a myriad of news perceived as bad. Albeit all that, the company posted a net profit of RM2.38 billion for the quarter. They have approximately 8.2 billion outstanding shares. This gives the company an EPS of RM0.29 for the quarter. Let's do a bit of calculating:

- Assume the profits don't increase (they are expected to, but we will be conservative).

- This would mean an EPS of RM1.16 for FY2021.

- This translates into a forward P/E of 6 at price RM7 (as of writing this, the price is RM6.84)

This make is one of the lowest valued stocks in the entire stock market, with only 5 companies having forward P/Es of below 6 at the time of writing this.

If we assume that a stock is fairly priced at P/E 15, this would mean that the fair value of Top Glove is RM17.40.

At the same time, one of Top Glove's main competitors in the glove manufacturing market - Hartalega, has a consensus forward P/E of about 19.5 based on its current market price.

Let's assume that the market assigns the same valuation to Top Glove as it does to its direct competitor and simiarly-sized peer Hartalega. In this case, Top Glove's market price would be RM22.62.

https://klse.i3investor.com/blogs/bursainvestments/2020-12-09-story-h1...

Today Top Glove released its 1QFY2021 report. You can access the full report here.

The stock has been trading at below RM7 level for the better part of the last few weeks on a myriad of news perceived as bad. Albeit all that, the company posted a net profit of RM2.38 billion for the quarter. They have approximately 8.2 billion outstanding shares. This gives the company an EPS of RM0.29 for the quarter. Let's do a bit of calculating:

- Assume the profits don't increase (they are expected to, but we will be conservative).

- This would mean an EPS of RM1.16 for FY2021.

- This translates into a forward P/E of 6 at price RM7 (as of writing this, the price is RM6.84)

This make is one of the lowest valued stocks in the entire stock market, with only 5 companies having forward P/Es of below 6 at the time of writing this.

If we assume that a stock is fairly priced at P/E 15, this would mean that the fair value of Top Glove is RM17.40.

At the same time, one of Top Glove's main competitors in the glove manufacturing market - Hartalega, has a consensus forward P/E of about 19.5 based on its current market price.

Let's assume that the market assigns the same valuation to Top Glove as it does to its direct competitor and simiarly-sized peer Hartalega. In this case, Top Glove's market price would be RM22.62.

https://klse.i3investor.com/blogs/bursainvestments/2020-12-09-story-h1...

Today Top Glove released its 1QFY2021 report. You can access the full report here.

The stock has been trading at below RM7 level for the better part of the last few weeks on a myriad of news perceived as bad. Albeit all that, the company posted a net profit of RM2.38 billion for the quarter. They have approximately 8.2 billion outstanding shares. This gives the company an EPS of RM0.29 for the quarter. Let's do a bit of calculating:

- Assume the profits don't increase (they are expected to, but we will be conservative).

- This would mean an EPS of RM1.16 for FY2021.

- This translates into a forward P/E of 6 at price RM7 (as of writing this, the price is RM6.84)

This make is one of the lowest valued stocks in the entire stock market, with only 5 companies having forward P/Es of below 6 at the time of writing this.

If we assume that a stock is fairly priced at P/E 15, this would mean that the fair value of Top Glove is RM17.40.

At the same time, one of Top Glove's main competitors in the glove manufacturing market - Hartalega, has a consensus forward P/E of about 19.5 based on its current market price.

Let's assume that the market assigns the same valuation to Top Glove as it does to its direct competitor and simiarly-sized peer Hartalega. In this case, Top Glove's market price would be RM22.62.

https://klse.i3investor.com/blogs/bursainvestments/2020-12-09-story-h1...

Today Top Glove released its 1QFY2021 report. You can access the full report here.

The stock has been trading at below RM7 level for the better part of the last few weeks on a myriad of news perceived as bad. Albeit all that, the company posted a net profit of RM2.38 billion for the quarter. They have approximately 8.2 billion outstanding shares. This gives the company an EPS of RM0.29 for the quarter. Let's do a bit of calculating:

- Assume the profits don't increase (they are expected to, but we will be conservative).

- This would mean an EPS of RM1.16 for FY2021.

- This translates into a forward P/E of 6 at price RM7 (as of writing this, the price is RM6.84)

This make is one of the lowest valued stocks in the entire stock market, with only 5 companies having forward P/Es of below 6 at the time of writing this.

If we assume that a stock is fairly priced at P/E 15, this would mean that the fair value of Top Glove is RM17.40.

At the same time, one of Top Glove's main competitors in the glove manufacturing market - Hartalega, has a consensus forward P/E of about 19.5 based on its current market price.

Let's assume that the market assigns the same valuation to Top Glove as it does to its direct competitor and simiarly-sized peer Hartalega. In this case, Top Glove's market price would be RM22.62.

https://klse.i3investor.com/blogs/bursainvestments/2020-12-09-story-h1...